Information on this site is not intended as medical advice and should not be used as a substitute for consulting with a qualified doctor.
Ocrelizumab is a recombinant humanized monoclonal antibody that selectively targets CD20-expressing B-cells 1. By reducing the number of these B cells, Ocrevus helps slow disease progression, reduce relapses, and limit the development of brain lesions .
In Bangladesh, Ocrevus is approved for the following indication(s)1:
OCREVUS is indicated for the treatment of patients with relapsing forms of multiple sclerosis (RMS) to suppress relapses and disease progression (clinical and subclinical disease activity).
OCREVUS is indicated for the treatment of patients with primary progressive multiple sclerosis (PPMS) to delay disease progression and reduce deterioration in walking speed.
For more disease and treatment related queries, it is recommended that you discuss with your physicians in details.
In Bangladesh, Ocrevus is available as
Vial 300 mg / 10 ml
To ensure patient safety and quality, it is strongly recommended to verify that, each medicine comes with the Roche Hologram Sticker, DGDA approved DAR (Drug Administration Registration) Number imprinted on it. Neither Radiant nor Roche Bangladesh takes liability of any other sources of products.
References
Ocrevus Product Information _ BD RO4964913_April 2022
Solutions